ArticleRadiation oncology (London, England)2014
Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
Article in Radiation oncology (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prevalence, risk factors, and interventions for female sexual dysfunction after radiotherapy for anal cancer: a systematic review.British journal of cancer · 2026Pooled it
- Incidence, Risk Factors, and Management of Radiotherapy-Related Skin Toxicity in Rectoanal Cancer Patients: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Clinical Practice Guideline: Anal Cancer—Diagnosis, Treatment and Follow-upDeutsches Arzteblatt international · 2021Guideline
- Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2018Pooled it
- Radio(chemo)therapy in anal cancer: evaluation of sex-specific disparities across AJCC stages.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- De Novo Primary Squamous Cell Carcinoma of the Prostate: Substantial Tumor Regression After Definitive Radiotherapy in a Medically Inoperable Patient.Life (Basel, Switzerland) · 2026Article
- Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV.The Lancet regional health. Western Pacific · 2023Article
- Article
- Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.Radiation oncology (London, England) · 2022Article
- Intensity-Modulated Radiotherapy Associated With Improved Survival Outcome in Anal Cancer.Frontiers in oncology · 2022Article
- Article
- Evolution of the Role of Radiotherapy for Anal Cancer.Cancers · 2021Review
- Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Quality of Life After Radiotherapy for Rectal and Anal Cancer.Current colorectal cancer reports · 2020Article
- Influence of radiation treatment technique on outcome and toxicity in anal cancer.Journal of radiation oncology · 2017Article
- Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer.Radiation oncology (London, England) · 2016Article
- Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the "bolus effect" of radiation therapy.JAAD case reports · 2015Article
- Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.World journal of gastroenterology · 2015Observational
- French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.Radiation oncology (London, England) · 2015Observational
- Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.Journal of gastrointestinal cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcurrent chemotherapy and radiation therapy is the preferred standard of care for patients with anal cancer. Several studies have suggested a benefit of intensity-modulated radiation therapy (IMRT) compared with 3D-conformal radiation (3D-CRT) regarding acute toxicity. This study evaluates outcome and toxicity of patients undergoing IMRT/Tomotherapy or 3D-CRT at our institution.
methodsA cohort of 105 anal cancer patients was treated with chemoradiation or radiation alone (16.2%) between January 2000 and December 2011. 37 patients received 3D-CRT while 68 patients were treated with IMRT. Follow-up exams were performed every 3 to 6 months for a minimum of 3 years and then annually.
resultsMedian follow-up was 41.4 months (2.8 - 158.4). Overall survival (OS), Progression-free survival (PFS) and local control (LC) at 3 years was 70.3%, 66.5%, 78.3% in the 3D-CRT group and 82.9%, 66.5%, 75.3% in the IMRT group without statistically significant difference. 3-year Colostomy-free survival (CFS) was 85.7% in the IMRT/Tomotherapy group and 91.8% in the 3D-CRT group (p = 0.48). No grade 4 toxicity was found in both groups. Severe (G2/3) acute skin toxicity (94.6% vs. 63.2%; p < 0.001) and acute gastrointestinal toxicity rate (67.6% vs. 47.1%; p = 0.03) was significantly higher with 3D-CRT compared to IMRT/Tomotherapy.
conclusionThe use of IMRT can reduce acute severe side effects of the skin and gastrointestinal tract but did not demonstrate improved results regarding OS, PFS, LC and CFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.